{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:06:11Z","timestamp":1781701571545,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"am","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases Now"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.idnow.2022.09.020","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T23:18:29Z","timestamp":1664234309000},"page":"104625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Population pharmacokinetics and pharmacodynamics of imipenem in neutropenic adult patients"],"prefix":"10.1016","volume":"53","author":[{"given":"M.","family":"Lafaurie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Burdet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hammas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Goldwirt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ber\u00e7ot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Sauvageon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Houze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fourmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mentr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idnow.2022.09.020_b0005","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idnow.2022.09.020_b0010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0732-8893(95)00053-D","article-title":"Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins","volume":"22","author":"Craig","year":"1995","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.idnow.2022.09.020_b0015","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/infdis\/158.4.831","article-title":"Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model","volume":"158","author":"Vogelman","year":"1988","journal-title":"J Infect Dis"},{"key":"10.1016\/j.idnow.2022.09.020_b0020","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/jac\/dkl354","article-title":"Two decades of imipenem therapy","volume":"58","author":"Rodloff","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2022.09.020_b0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1086\/514622","article-title":"The Pharmacodynamics of \u03b2-Lactams","volume":"27","author":"Turnidge","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idnow.2022.09.020_b0030","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/BF01700408","article-title":"Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish study group","volume":"16","author":"Nyhl\u00e9n","year":"1997","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idnow.2022.09.020_b0035","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1473-3099(08)70228-7","article-title":"Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia","volume":"8","author":"Lortholary","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idnow.2022.09.020_b0040","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1128\/AAC.31.9.1420","article-title":"Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients","volume":"31","author":"Drusano","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2022.09.020_b0045","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12094-018-1983-4","article-title":"SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018)","volume":"21","author":"Carmona-Bayonas","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.idnow.2022.09.020_b0050","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.csda.2006.05.007","article-title":"Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model","volume":"51","author":"Samson","year":"2006","journal-title":"Comput Stat Data Anal"},{"key":"10.1016\/j.idnow.2022.09.020_b0055","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.idnow.2022.09.020_b0060","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40262-013-0086-1","article-title":"Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations","volume":"52","author":"Goulenok","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.idnow.2022.09.020_b0065","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/00365540151060941","article-title":"Pharmacokinetics of ceftazidime in febrile neutropenic patients","volume":"33","author":"Nyhl\u00e9n","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.idnow.2022.09.020_b0070","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijantimicag.2005.09.016","article-title":"Trough serum concentrations of beta-lactam antibiotics in cancer patients: inappropriateness of conventional schedules to pharmacokinetic\/pharmacodynamic properties of beta-lactams","volume":"27","author":"Navas","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idnow.2022.09.020_b0075","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1128\/AAC.00891-08","article-title":"Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies","volume":"53","author":"Lamoth","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2022.09.020_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idnow.2022.09.020_b0085","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2165\/00003088-200544070-00007","article-title":"Relationship between minimum inhibitory concentration and stationary concentration revisited: growth rates and minimum bactericidal concentrations","volume":"44","author":"Mouton","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.idnow.2022.09.020_b0090","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00003088-200544020-00005","article-title":"Pharmacokinetic\/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration","volume":"44","author":"Mouton","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.idnow.2022.09.020_b0095","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2165\/00003088-199835050-00004","article-title":"Continuous infusion of beta-lactam antibiotics","volume":"35","author":"MacGowan","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.idnow.2022.09.020_b0100","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/infdis\/159.2.281","article-title":"Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models","volume":"159","author":"Leggett","year":"1989","journal-title":"J Infect Dis"},{"key":"10.1016\/j.idnow.2022.09.020_b0105","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/2110-5820-2-22","article-title":"Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?","volume":"2","author":"Van Herendael","year":"2012","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.idnow.2022.09.020_b0110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1345\/aph.1E271","article-title":"Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia","volume":"39","author":"Ariano","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.idnow.2022.09.020_b0115","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.bcp.2005.12.003","article-title":"Redefining penems","volume":"71","author":"Dalhoff","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.idnow.2022.09.020_b0120","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13054-018-2155-1","article-title":"Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients","volume":"22","author":"Veiga","year":"2018","journal-title":"Crit Care"}],"container-title":["Infectious Diseases Now"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991922002123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991922002123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:32:14Z","timestamp":1763019134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666991922002123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2666991922002123"],"URL":"https:\/\/doi.org\/10.1016\/j.idnow.2022.09.020","relation":{},"ISSN":["2666-9919"],"issn-type":[{"value":"2666-9919","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics and pharmacodynamics of imipenem in neutropenic adult patients","name":"articletitle","label":"Article Title"},{"value":"Infectious Diseases Now","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idnow.2022.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104625"}}